This has important implications in terms of a future therapeutic approach in humans with peripheral neuropathy as topical delivery of M1R antagonists to sensory nerve endings may prove sufficient to activate AMPK in neuronal cell bodies and promote neuroprotection and nerve regrowth without requiring concurrent systemic exposure at concentrations likely to block M1R in other organs. This evidence concerns the gene CHRM1 and peripheral neuropathy.